Altered surface marker expression and function of G-CSF-induced neutrophils from test subjects and patients under chemotherapy.
We have previously reported an altered surface marker expression and chemotaxis of G-CSF-induced neutrophils from patients with severe congenital neutropenia. However, effects of G-CSF and influence of the underlying disease on neutrophils could not be discerned. In this study we have evaluated the effects of G-CSF on neutrophil phenotype and function in patients under chemotherapy and in healthy test subjects. We found a significantly enhanced expression of Fc gamma RI, CD14 and CD54 and a decrease in the level of Fc gamma RIII during G-CSF treatment. In addition, motility of G-CSF-induced neutrophils was significantly decreased. The effects were seen in patients under cytotoxic chemotherapy and in healthy test subjects. Surface marker alterations and neutrophil motility were affected by G-CSF administration in a dose-dependent manner. Kinetic studies on neutrophils from healthy test subjects demonstrated that all effects could be seen after a single administration of 300 micrograms G-CSF and began to appear within 4 h. Release of partially immature neutrophils from the bone marrow and indirect activation of these cells by G-CSF are discussed as possible reasons for the findings presented. They demonstrate that G-CSF has profound effects on neutrophil phenotype and function in vivo which might have clinical implications.
Spiekermann
K
K
Department of Haematology and Oncology, Medical School Hannover, Germany.
Emmendoerffer
A
A
Elsner
J
J
Raeder
E
E
Lohmann-Matthes
M L
ML
Prahst
A
A
Link
H
H
Freund
M
M
Welte
K
K
Roesler
J
J
D000954:Antigens, Surface / Q000097:blood*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002634:Chemotaxis, Leukocyte; D004306:Dose-Response Relationship, Immunologic; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology* / Q000502:physiology; D017452:Receptors, IgG / Q000032:analysis; D011994:Recombinant Proteins / Q000494:pharmacology
D000954:Antigens, Surface; D000970:Antineoplastic Agents; D017452:Receptors, IgG; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor